Prima BioMed (IMMP) Competitors $1.77 +0.13 (+7.93%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.73 -0.04 (-2.20%) As of 08/22/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. VERV, LENZ, PRAX, RCUS, AVXL, GPCR, SYRE, AKBA, PHAR, and CRONShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Verve Therapeutics (VERV), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Verve Therapeutics LENZ Therapeutics Praxis Precision Medicines Arcus Biosciences Anavex Life Sciences Structure Therapeutics Spyre Therapeutics Akebia Therapeutics Pharming Group Cronos Group Prima BioMed (NASDAQ:IMMP) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Do insiders and institutionals have more ownership in IMMP or VERV? 2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 19.3% of Verve Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate IMMP or VERV? Prima BioMed presently has a consensus target price of $7.00, suggesting a potential upside of 295.48%. Verve Therapeutics has a consensus target price of $14.57, suggesting a potential upside of 30.92%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Verve Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Verve Therapeutics 0 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is IMMP or VERV more profitable? Prima BioMed has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Prima BioMed's return on equity of 0.00% beat Verve Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Verve Therapeutics -303.64%-35.81%-27.57% Which has better earnings & valuation, IMMP or VERV? Prima BioMed has higher earnings, but lower revenue than Verve Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M50.55-$28.01MN/AN/AVerve Therapeutics$32.33M30.69-$198.71M-$2.11-5.27 Which has more risk and volatility, IMMP or VERV? Prima BioMed has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Does the media prefer IMMP or VERV? In the previous week, Prima BioMed's average media sentiment score of 0.00 equaled Verve Therapeutics'average media sentiment score. Company Overall Sentiment Prima BioMed Neutral Verve Therapeutics Neutral SummaryPrima BioMed beats Verve Therapeutics on 7 of the 12 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.73M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.05Price / Sales50.55342.28432.51103.82Price / CashN/A43.1937.7358.48Price / Book1.698.129.536.61Net Income-$28.01M-$54.72M$3.26B$265.56M7 Day Performance2.31%2.63%2.10%1.97%1 Month Performance5.36%2.78%2.81%-0.36%1 Year Performance-27.16%11.01%30.56%19.03% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.1554 of 5 stars$1.77+7.9%$7.00+295.5%-26.3%$240.73M$5.14M0.002,021Upcoming EarningsVERVVerve Therapeutics3.004 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110LENZLENZ Therapeutics1.2811 of 5 stars$38.77+11.8%$49.60+27.9%+80.0%$989.15MN/A-20.41110Gap UpHigh Trading VolumePRAXPraxis Precision Medicines1.7277 of 5 stars$44.95-2.2%$95.22+111.8%-2.0%$966.84M$8.55M-3.66110RCUSArcus Biosciences2.4173 of 5 stars$9.19+1.4%$21.14+130.2%-40.6%$964.27M$258M-2.90500Positive NewsAVXLAnavex Life Sciences3.8959 of 5 stars$11.35+2.4%$44.00+287.7%+55.5%$946.42MN/A-20.6440Analyst ForecastGPCRStructure Therapeutics2.5137 of 5 stars$17.51+7.4%$75.71+332.4%-49.9%$939.42MN/A-16.68136News CoverageSYRESpyre Therapeutics2.905 of 5 stars$15.25+0.6%$53.40+250.2%-29.8%$915.68M$890K-4.4973AKBAAkebia Therapeutics4.0067 of 5 stars$3.35-2.0%$6.75+101.5%+117.0%$906.80M$160.18M-19.70430PHARPharming Group2.4169 of 5 stars$12.10-8.5%$30.00+147.9%+72.3%$906.45M$297.20M-93.08280Gap UpHigh Trading VolumeCRONCronos Group0.7578 of 5 stars$2.67+16.1%N/A+12.6%$882.76M$117.61M53.40450High Trading Volume Related Companies and Tools Related Companies Verve Therapeutics Alternatives LENZ Therapeutics Alternatives Praxis Precision Medicines Alternatives Arcus Biosciences Alternatives Anavex Life Sciences Alternatives Structure Therapeutics Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Pharming Group Alternatives Cronos Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access